Restless Legs Syndrome: Pathophysiology and the Role of Iron and Folate

Total Page:16

File Type:pdf, Size:1020Kb

Restless Legs Syndrome: Pathophysiology and the Role of Iron and Folate Alternative Medicine Review Volume 12, Number 2 2007 Review Article Restless Legs Syndrome: Pathophysiology and the Role of Iron and Folate Lyn Patrick, ND A study of 23,052 primary care patients evalu- ated for RLS revealed that nine percent had weekly symptoms of RLS. Although the majority of those di- agnosed (88%) had primary complaints of insomnia, Abstract only 13 percent had actually received a prior diagnosis of RLS.2 Of those who had received a prior diagnosis, Restless Legs Syndrome (RLS) is a common movement disorder the majority had been prescribed therapies known to characterized by a circadian variation in symptoms involving be ineffective in RLS. Misdiagnoses included varicose an urge to move the limbs, usually the legs. Pregnant women, veins, other venous disorders, depression, myalgia, back patients with end-stage renal disease or iron-deficiency anemia, or spinal injury, and diabetic neuropathy. and children with attention deficit hyperactivity disorder (AD/ HD) have a significantly higher prevalence of RLS. The classic Diagnostic Criteria presentation includes the onset or worsening of symptoms when RLS is classified as either familial (primary at rest and the circadian pattern of exacerbation of symptoms RLS), with a clear genetic component, or acquired (sec- at night. These symptoms reflect a circadian fluctuation of ondary RLS). Primary RLS occurs in approximately 50 dopamine in the substantia nigra. Patients with RLS have lower percent of first-degree relatives of those with RLS and is levels of dopamine in the substantia nigra and respond to iron believed to be related to an inherited defect in dopamine administration. Iron, as a cofactor in dopamine production, plays metabolism.11 Acquired RLS involves altered iron me- a central role in the etiology of RLS. Folic acid administration tabolism and occurs in a variety of patient populations, has also been shown to alleviate the symptoms of RLS and including pregnant women, patients with end-stage re- 12 may play a role in the treatment of primary (familial) RLS. nal disease, and individuals with iron deficiency. (Altern Med Rev 2007;12(2):101-112) The diagnosis of RLS consists of four essential clinical criteria based solely on symptoms (Table 1).13 A compelling urge to move the limbs occurs on resting or Introduction lying down and discomfort is alleviated by movement of Restless Legs Syndrome (RLS) is a neurologi- a body part (usually the legs) or the entire body. RLS is cal movement disorder that is common, under-diag- also characterized by involuntary or spontaneous move- nosed, under-treated, and has a poorly understood eti- 1 ment, such as floor pacing, tossing and turning in bed, ology. Due to a lack of awareness among primary care and rubbing the legs to relieve sensations – described providers, both misdiagnosis and mistreatment of RLS appear to be common.2 Studies in North America and Northern Europe confirm RLS is a common disorder Lyn Patrick, ND – Bastyr University graduate 1984; Private practice, Durango, with a prevalence of 5-25 percent in the general popu- CO, specializing in Environmental Medicine and chronic hepatitis C; Faculty of lation.3-8 It is twice as prevalent in women,9 and more the postgraduate Certification Course in Environmental Medicine, Southwest College of Naturopathic Medicine; Contributing Editor, Alternative Medicine common in the elderly, with 10-20 percent over age 65 Review; Physician-member of the Hepatitis C Ambassadors Team. experiencing significant symptomology.10 Correspondence address: 117 CR 250 Suite A, Durango, CO 81301. Email: [email protected] Page 101 Copyright © 2007 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission. Alternative Medicine Review Volume 12, Number 2 June 2007 Alternative Medicine Review Volume 12, Number 2 2007 Restless Legs Syndrome as “creeping, crawling, itching, burning, sear- Table 1. Essential Clinical Criteria for Diagnosis of RLS ing, tugging, drawing, aching, like an electric current.”1 The symp- 1. A sensation of an urge to move the limbs (commonly legs) – usually toms have a circadian associated with paresthesia pattern – always im- proved when at rest in 2. Onset or worsening of symptoms when at rest – not associated with the morning and worse any specific body position. when at rest in the eve- 13 ning. 3. Relief of symptoms with movement; complete relief immediately or shortly after initiating movement. Differential Diagnosis 4. Marked circadian variation in degree or occurrence of symptoms; Several other worse in the evening, improved in the morning regardless of quality disorders resemble RLS or quantity of sleep. and are differentiated by symptom descrip- tion, laboratory testing, and other appropri- ate diagnostic workup (Table 2).14 Neuropathies and (fasting), thyroid hormone, vitamin B6, and vitamin radiculopathies can be ruled in or out by electrophysi- B12.15 Abnormalities of any of these would help rule ological assessment and testing blood levels of glucose out RLS. Table 2. Differential Diagnosis – to Differentiate from RLS Peripheral Neuropathy No circadian changes No periodic leg movements in sleep Nerve conduction abnormal No improvement with movement Akathisia No circadian pattern No paresthesia Improvement from dopamine blockers Peripheral Vascular Disease Worse with movement, better with rest Vascular and skin changes seen on exam Nocturnal Leg Cramps Unilateral, focal, sudden severe onset Painful Legs and Moving Toes No urge to move, no worsening at rest or improvement with movement No circadian changes Page 102 Copyright © 2007 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission. Alternative Medicine Review Volume 12, Number 2 June 2007 Alternative Medicine Review Volume 12, Number 2 2007 Review Article results in sleep impairment equal to or greater than any other sleep disorder. In one polysomnographic study of Table 3. Populations At-Risk for Restless 26 RLS patients, sleep efficiency was decreased by 50 Legs Syndrome percent, leaving 30 percent of patients with less than 3.5 full hours of sleep nightly.12 With the exception of Pregnancy mania, severe RLS results in the greatest level of sleep deprivation of any sleep disorder.12 End-stage renal disease on hemodialysis Given recent findings that show 30-40 percent of those with chronic insomnia may also have clinical Primary family history of RLS depression, this level of sleep deprivation may be related to the significantly higher incidence of anxiety and de- Iron deficiency anemia pression in RLS patients compared to the general pop- ulation.18 Patients presenting in a sleep disorder clinic with either RLS or periodic leg movement disorder Frequent blood donations (PLMD) had a greater than 50 percent chance of hav- ing some form of depression.20 The negative impact of Gastric surgery RLS on quality of life has been shown to be equal to or greater than chronic obstructive pulmonary disease or Pediatric AD/HD myocardial infarction.12 At-Risk Populations for RLS Pregnancy, end-stage renal disease, certain RLS: A Cause of Serious Sleep medications, and iron deficiency are associated with a 15 Impairment significantly higher incidence of RLS (Table 3). RLS is a form of sleep disorder that includes periodic limb movements in sleep (PLMS), a condition Pregnancy where involuntary motor movements of the limbs occur During pregnancy the incidence of iron defi- during the sleep cycle and lead to a shift in sleep stage ciency is significant; less than optimal iron intake can 21 and repeated awakenings.12 PLMS can also occur in occur in 90 percent of pregnant American women. conditions such as narcolepsy, Parkinson’s disease, and Research estimates 11-27 percent of pregnant women other disorders related to impairments in dopamine experience RLS at some point during pregnancy, most 22-24 production.16 PLMS is more prevalent as age increases commonly in the third trimester. RLS is the most – up to 30 percent of individuals over age 50 experience common movement disorder in pregnancy and gener- 25 PLMS secondary to a disease state or medication side ally remits with delivery. effect.17 The etiology of RLS in pregnancy is related Approximately 20 percent of those with RLS to iron and folate insufficiency. During normal preg- do not have involuntary motor movements during sleep nancy, the requirements for both nutrients increase (it is not necessary for a diagnosis). However, the condi- significantly – iron requirement increases 3- to 4-fold 22 tion results in severe sleep disruption for the majority and folate requirement increases 8- to 10-fold. Defi- of RLS patients and has been recognized as a cause of ciencies of either nutrient have been found in pregnant sleep impairment in 5-10 percent of the U.S. popula- women with RLS, and the resolution of RLS appears tion.18 Because PLMS leads to multiple awakenings to correlate with normalization of folate and iron levels 26 at night, RLS is considered the fourth-leading cause postpartum. The prevalence of RLS in women receiv- of insomnia. Sleep impairment, although usually not ing folate supplementation throughout pregnancy was voluntarily disclosed without direct questioning, is the significantly lower compared to the prevalence in wom- main complaint described by those with RLS.19 RLS en with no folate supplementation (9% versus 80%, respectively).27 Page 103 Copyright © 2007 Thorne Research, Inc. All Rights Reserved. No Reprint Without Written Permission. Alternative Medicine Review Volume 12, Number 2 June 2007 Alternative Medicine Review Volume 12, Number 2 2007 Restless Legs Syndrome In a prospective trial of pregnant wom- en with RLS and matched pregnant controls, he- Figure 1. Changes in Serum Folate from Preconception moglobin and serum folate, iron, ferritin (storage until One-month Postpartum iron), and vitamin B12 were monitored precon- 26 ception and once each trimester. Although no 18 serum folate measurements fell below the normal range of 4-20 ng/mL, folate levels were signifi- 16 cantly lower in the RLS group (Figure 1) prior to 14 conception and during the ensuing nine months.
Recommended publications
  • Substantia Nigra Integrity Correlates with Sequential Working Memory in Parkinson’S Disease
    Research Articles: Behavioral/Cognitive Substantia nigra integrity correlates with sequential working memory in Parkinson’s disease https://doi.org/10.1523/JNEUROSCI.0242-21.2021 Cite as: J. Neurosci 2021; 10.1523/JNEUROSCI.0242-21.2021 Received: 1 February 2021 Revised: 6 May 2021 Accepted: 12 May 2021 This Early Release article has been peer-reviewed and accepted, but has not been through the composition and copyediting processes. The final version may differ slightly in style or formatting and will contain links to any extended data. Alerts: Sign up at www.jneurosci.org/alerts to receive customized email alerts when the fully formatted version of this article is published. Copyright © 2021 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license, which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. 1 Research Article 2 Substantia nigra integrity correlates with sequential working 3 memory in Parkinson’s disease 4 Running title: substantia nigra & sequential memory in PD 5 Wenyue Liu 1,2, Changpeng Wang 3, Tingting He 3, Minghong Su 2,4, Yuan Lu 1, 6 Guanyu Zhang 2,4, Thomas F. Münte 5, Lirong Jin 3,*, Zheng Ye 1,6,* 7 1Institute of Neuroscience, Key Laboratory of Primate Neurobiology, Center for 8 Excellence in Brain Science and Intelligence Technology, Chinese Academy of 9 Sciences, Shanghai 200031, China 10 2University of Chinese Academy of Sciences, Beijing 100049, China 11 3Department of Neurology, Zhongshan Hospital, Fudan University, Shanghai 200032, 12 China 13 4Institute of Psychology, Chinese Academy of Sciences, Beijing 100101, China 14 5Department of Neurology, University of Lübeck, Lübeck 23538, Germany 15 6Shanghai Center for Brain Science and Brain-Inspired Intelligence Technology, 16 Shanghai 201210, China 17 18 WL, CW, and TH equally contributed to this work.
    [Show full text]
  • Contrast Mechanisms Associated with Neuromelanin-MRI
    Contrast mechanisms associated with Neuromelanin-MRI Paula Trujillo1,2, Paul Summers1, Emanuele Ferrari3, Fabio A. Zucca3, Michela Sturini4, Luca Mainardi2, Sergio Cerutti2, Alex K Smith5,6, Seth A Smith5,6,7, Luigi Zecca3, Antonella Costa1 1 Department of Neuroradiology, Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, Milan, MI, Italy 2 Department of Electronics, Information and Bioengineering, Politecnico di Milano, Milan, MI, Italy 3 Institute of Biomedical Technologies, National Research Council of Italy, Segrate, MI, Italy 4 Department of Chemistry, University of Pavia, Pavia, PV, Italy 5 Vanderbilt University Institute of Imaging Science, Vanderbilt University, Nashville, TN, USA 6 Department of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA 7 Department of Radiology and Radiological Sciences, Vanderbilt University, Nashville, TN, USA Full postal and email address of the corresponding author: Paula Trujillo Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico Department of Neuroradiology Via F. Sforza 35 20122, Milan, MI, Italy Email: [email protected] Abbreviations: BSA = bovine serum albumin; DS = direct saturation; LC = locus coeruleus; MT = magnetization transfer; NM = Neuromelanin; PD = Parkinson’s Disease; PSR = pool size ratio; qMT = quantitative MT; RF = radiofrequency; SN = Substantia Nigra; TSE = turbo spin echo. Abstract Purpose: To investigate the physical mechanisms associated with the contrast observed in neuromelanin-MRI. Methods: Phantoms having different concentrations of synthetic melanins with different degrees of iron loading were examined on a 3T scanner using relaxometry and quantitative magnetization transfer (MT). Results: Concentration-dependent T1- and T2-shortening was most pronounced for the melanin pigment when combined with iron. Metal-free melanin had a negligible effect on the magnetization transfer spectra.
    [Show full text]
  • Neuromelanin MR Imaging in Parkinson's Disease
    Oruen – The CNS Journal Review article Neuromelanin MR imaging in Parkinson’s disease Sofia Reimão1,2,4, Joaquim J Ferreira3,4,5,6 1 Neurological Imaging Department, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal 2 Imaging University Clinic, Faculty of Medicine, University of Lisbon, Portugal 3 Department of Neurosciences, Hospital de Santa Maria - Centro Hospitalar Lisboa Norte, Portugal 4 Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine, University of Lisbon, Portugal 5 Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine, University of Lisbon, Portugal 6 CNS – Campus Neurológico Sénior, Torres Vedras, Portugal Received – 24 April 2016; accepted – 04 May 2016 ABSTRACT The development and application of neuromelanin sensitive MR imaging has allowed the detection of significant changes in the substantia nigra (SN) of Parkinson’s disease (PD) patients, with high sensitivity and specificity in differentiating PD patients from non-PD aged controls, even in early disease stages, namely at the time of clinical diagnosis. These MR neuromelanin changes in the SN of PD patients reproduced in vivo long known characteristic pathological changes of PD. Several image evaluation methods have been used, corroborating the reproducibility of the data and enabling wider applications of this imaging technique in the clinical practice. In this review we analyze the background and the technical aspects of neuromelanin sensitive MR imaging, focusing on the applications of these specific
    [Show full text]
  • Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra
    brain sciences Article Semi-Automatic Signature-Based Segmentation Method for Quantification of Neuromelanin in Substantia Nigra Gašper Zupan 1, Dušan Šuput 1,* , Zvezdan Pirtošek 1,2 and Andrej Vovk 1 1 Faculty of Medicine, University of Ljubljana, Vrazov trg 2, 1000 Ljubljana, Slovenia; [email protected] (G.Z.); [email protected] (Z.P.); [email protected] (A.V.) 2 Department of Neurology, University Medical Center, Zaloška 2, 1000 Ljubljana, Slovenia * Correspondence: [email protected]; Tel.: +386-1-543-7821 Received: 23 October 2019; Accepted: 19 November 2019; Published: 22 November 2019 Abstract: In Parkinson’s disease (PD), there is a reduction of neuromelanin (NM) in the substantia nigra (SN). Manual quantification of the NM volume in the SN is unpractical and time-consuming; therefore, we aimed to quantify NM in the SN with a novel semi-automatic segmentation method. Twenty patients with PD and twelve healthy subjects (HC) were included in this study. T1-weighted spectral pre-saturation with inversion recovery (SPIR) images were acquired on a 3T scanner. Manual and semi-automatic atlas-free local statistics signature-based segmentations measured the surface and volume of SN, respectively. Midbrain volume (MV) was calculated to normalize the data. Receiver operating characteristic (ROC) analysis was performed to determine the sensitivity and specificity of both methods. PD patients had significantly lower SN mean surface (37.7 8.0 vs. ± 56.9 6.6 mm2) and volume (235.1 45.4 vs. 382.9 100.5 mm3) than HC. After normalization ± ± ± with MV, the difference remained significant.
    [Show full text]
  • A Novel Method for Creating a Synthetic L-DOPA Proteome and in Vitro Evidence of Incorporation
    proteomes Article A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro Evidence of Incorporation Joel Ricky Steele 1,2,* , Natalie Strange 3 , Kenneth J. Rodgers 2 and Matthew P. Padula 1 1 Proteomics Core Facility and School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; [email protected] 2 Neurotoxin Research Group, School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; [email protected] 3 School of Life Sciences, The University of Technology Sydney, Ultimo, NSW 2007, Australia; [email protected] * Correspondence: [email protected] Abstract: Proteinopathies are protein misfolding diseases that have an underlying factor that affects the conformation of proteoforms. A factor hypothesised to play a role in these diseases is the incorporation of non-protein amino acids into proteins, with a key example being the therapeutic drug levodopa. The presence of levodopa as a protein constituent has been explored in several studies, but it has not been examined in a global proteomic manner. This paper provides a proof-of-concept method for enzymatically creating levodopa-containing proteins using the enzyme tyrosinase and provides spectral evidence of in vitro incorporation in addition to the induction of the unfolded protein response due to levodopa. Keywords: misincorporation; post-translational modifications; PTM; Levodopa; L-DOPA Citation: Steele, J.R.; Strange, N.; Rodgers, K.J.; Padula, M.P. A Novel Method for Creating a Synthetic L-DOPA Proteome and In Vitro 1. Introduction Evidence of Incorporation. Proteomes 2021, 9, 24. https://doi.org/10.3390/ The non-protein amino acid (NPAA) L-3,4-dihydroxyphenylalanine (L-DOPA), com- proteomes9020024 mercially known as ‘levodopa’, is used to restore dopamine levels in the damaged substan- tia nigra of Parkinson’s disease (PD) patients [1] although it has also been hypothesised to Academic Editors: Jacek accelerate PD pathology and neurodegeneration [2] by causing neuronal toxicity [2–16].
    [Show full text]
  • Insights Into Parkinson's Disease from Computational Models Of
    bioRxiv preprint doi: https://doi.org/10.1101/260992; this version posted February 12, 2018. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Insights into Parkinson's disease from computational models of the basal ganglia Mark D. Humphries1;2∗, Jose Obeso3 and Jakob Kisbye Dreyer4;5 1. Faculty of Biology, Medicine, and Health, University of Manchester, Manchester, UK. 2. Department of Psychology, University of Nottingham, Nottingham, UK 3. HM-CINAC,Hospital Puerta del Sur, Mostoles, CEU-San Pablo University and CIBERNED, Instituto Carlos III, Madrid, Spain 4. Department of Neuroscience, University of Copenhagen, Copenhagen, Denmark 5. Department of Bioinformatics, H Lundbeck A/S, DK-2500 Valby, Denmark ∗ Corresponding author: [email protected] Abstract Movement disorders arise from the complex interplay between multiple changes to neural circuits, and between those changes and their compensatory mechanisms. Treatments, when available, either have incompletely understood mechanisms of ac- tion, or unknown routes from these mechanisms to the amelioration of the disorder's symptoms. Using Parkinson's disease as a case-study, we review here how compu- tational models are a crucial tool for taming this complexity, across causative mech- anisms, consequent neural dynamics, and treatments. For mechanisms, we review models that capture the effects of losing dopamine on basal ganglia function; for dynamics, we discuss models that have transformed our understanding of how beta- band (15-30 Hz) oscillations arise in the parkinsonian basal ganglia.
    [Show full text]
  • Neuromelanin Biosynthesis Is Driven by Excess Cytosolic Catecholamines Not Accumulated by Synaptic Vesicles
    Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles David Sulzer*†‡§, Johanna Bogulavsky*, Kristin E. Larsen*, Gerald Behr*, Erdem Karatekin¶, Mark H. Kleinman¶, Nicholas Turro¶, David Krantzʈ, Robert H. Edwardsʈ, Lloyd A. Greene**, and Luigi Zecca†† Departments of *Neurology, †Psychiatry, **Pathology, and ¶Chemistry, Columbia University, New York, NY 10032; ‡Department of Neuroscience, New York State Psychiatric Institute, New York, NY 10032; ʈDepartment of Neurology, University of California, San Francisco, CA 94143; and ††Institute of Advanced Biomedical Technologies, Consiglio Nazionale delle Ricerche, 20090 Segrate, Italy Contributed by Nicholas Turro, August 25, 2000 Melanin, the pigment in hair, skin, eyes, and feathers, protects oxidation in the test tube (13), that substance differs from external tissue from damage by UV light. In contrast, neuromelanin biological NM (10, 14, 15). In contrast, biological NM is located (NM) is found in deep brain regions, specifically in loci that in subcellular organelles known as NM granules (16). To address degenerate in Parkinson’s disease. Although this distribution sug- long-standing questions on the synthesis, characterization, and gests a role for NM in Parkinson’s disease neurodegeneration, the functional role of NM granules, we have induced formation of biosynthesis and function of NM have eluded characterization NM in SN neuronal cell culture and a catecholaminergic cell line. because of lack of an experimental system. We induced NM in rat substantia nigra and PC12 cell cultures by exposure to L-dihydroxy- Methods phenylalanine, which is rapidly converted to dopamine (DA) in the SNC Cultures. Postnatally derived cultures of ventral midbrain cytosol. This pigment was identical to human NM as assessed by neurons derived from Sprague–Dawley rats were prepared as paramagnetic resonance and was localized in double membrane described (17, 18).
    [Show full text]
  • Parkinson's Disease and Melanoma. What Is the Possible Link?
    REVIEW ARTICLE Magdalena Chrabąszcz, Joanna Czuwara, Lidia Rudnicka Department of Dermatology, Medical University of Warsaw, Poland Odd correlation: Parkinson’s disease and melanoma. What is the possible link? Address for correspondence: ABSTRACT Dr n. med. Joanna Czuwara Parkinson’s disease (PD) is a neurodegenerative disorder, characterised by depletion of dopamine in the stria- Katedra i Klinika Dermatologiczna tum and loss of melanin-positive, dopaminergic neurons in the substantia nigra. Melanoma is a skin neoplasm Warszawskiego Uniwersytetu Medycznego arising from epidermal melanocytes. The epidemiology of melanoma focuses on well-known risk factors such ul. Koszykowa 82a, Warszawa 02–008 as light skin and hair colour, gender, eye pigmentation, and ultraviolet (UV) exposure. Many studies have sug- Tel.: 22 502 13 11 gested an association between Parkinson’s disease and melanoma. The mechanism underlying the possible e-mail: [email protected] connection between PD and melanoma is not clear and has aroused lots of interest. More interesting is that the link between these two diseases runs both ways. What is the underlying cause of this reciprocal association? Is it due to Parkinson’s treatment? Is levodopa the reason for increased incidence of melanoma in people with the neurodegenerative condition? Are there any genetic, immune system irregularities or environmental risk factors that serve as the common denominator between these two conditions? Should we consider melanoma comorbidity with Parkinson’s disease and vice versa? Some hypotheses include pigmentation changes in melanin and/or melanin synthesis enzyme like tyrosinase hydroxylase, autophagy deficits, disturbed form of metabolically controlled cell death, and changes of PD-related genes such as Parkin or a-synuclein.
    [Show full text]
  • Reproducibility Assessment of Neuromelanin-Sensitive Magnetic Resonance Imaging Protocols for Region-Of-Interest and Voxelwise A
    bioRxiv preprint doi: https://doi.org/10.1101/781815; this version posted September 25, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 1 1 Reproducibility Assessment of Neuromelanin-Sensitive Magnetic 2 Resonance Imaging Protocols for Region-of-Interest and Voxelwise 3 Analyses 4 5 Kenneth Wengler1,2, Xiang He3, Anissa Abi-Dargham3,4*, and Guillermo Horga1* 6 7 1: Department of Psychiatry, Columbia University, New York, NY, USA 8 2: Department of Biomedical Engineering, Stony Brook University, Stony Brook, NY, 9 USA 10 3: Department of Radiology, Stony Brook University, Stony Brook, NY, USA 11 4: Department of Psychiatry, Stony Brook University, Stony Brook, NY, USA 12 *: These authors contributed equally 13 14 15 Corresponding Author: Kenneth Wengler, PhD 16 Department of Psychiatry, Columbia University 17 Division of Translational Imaging, New York State Psychiatric Institute 18 1051 Riverside Dr, Unit 31 19 New York, NY 10032 20 Phone: 646-774-5571 21 Email: [email protected] bioRxiv preprint doi: https://doi.org/10.1101/781815; this version posted September 25, 2019. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. 2 1 Highlights 2 • A detailed NM-MRI volume placement protocol is described. 3 • Guidelines covering acquisition through analysis for NM-MRI are given. 4 • A test-retest study in 10 healthy subjects shows high reproducibility for region-of- 5 interest (ROI) and voxelwise analyses.
    [Show full text]
  • Introduction to Neuroscience: the Basal Ganglia
    Introduction to Neuroscience: The Basal Ganglia Michal Rivlin Basal Ganglia– a group of subcortical nuclei • Striatum: caudate & putamen • Globus pallidus (external & internal segments) • Subthalamic nucleus • Substantia nigra (pars compacta & pars reticulata) Basal ganglia-thalamo-cortical loop • Basal Ganglia receives robust input from the cortex • Principal projection of the BG – via the thalamus back to cortical targets Overview of BG organization • Input: Output: – Caudate and putamen (together, the Substantia nigra pars reticulata (SNr) striatum) Internal segment of globus pallidus (GPi) • Intrinsic: – Subthalamic nucleus (STN) Neuromodulator: – External segment of globus pallidus Substantia nigra pars compacta (SNc) (GPe) SNc Striatum: Medium spiny neurons • Caudate and putamen • Medium spiny neurons – 95% of neurons; primary projection neurons – GABAergic; inhibitory – Very little spontaneous activity Striatum: Intrinsic interneurons 2 principle types – 3 GABAergic interneurons – Tonically active neurons (TANs) • Cholinergic • Large cell bodies GloBus pallidus Two segments Internal (GPi): Principle output nucleus External (GPe): intrinsic circuitry GABAergic; inhibitory high tonic firing rates GloBus pallidus Elias et al. J. Neurosci. 2007 SuBthalamic nucleus Glutamatergic; excitatory Substantia nigra • Midbrain SNc • SN pars reticulata (SNr) – GABAergic – high tonic firing rates – Output of BG • SN pars compacta (SNc) – Neuromelanin- containing cells – Dopaminergic – Tonic/phasic firing Direct and indirect pathways Direct pathway
    [Show full text]
  • A Study of Single Substantia Nigra Neurons
    ORIGINAL CONTRIBUTION Relationship Between Mitochondria and ␣-Synuclein A Study of Single Substantia Nigra Neurons Amy K. Reeve, PhD; Tae-Kyung Park, BSc; Evelyn Jaros, PhD; Graham R. Campbell, PhD; Nichola Z. Lax, PhD; Philippa D. Hepplewhite, BSc; Kim J. Krishnan, PhD; Joanna L. Elson, PhD; Christopher M. Morris, PhD; Ian G. McKeith, MD; Doug M. Turnbull, MD Objective: To explore the relationship between ␣-sy- pathology and cell loss. Patients with dementia with Lewy nuclein pathology and mitochondrial respiratory chain bodies and idiopathic Parkinson disease fulfilled the clini- protein levels within single substantia nigra neurons. cal and neuropathologic criteria for these diseases. Design: We examined ␣-synuclein and mitochondrial Results: Our results showed that mitochondrial den- protein expression in substantia nigra neurons of 8 pa- sity is the same in nigral neurons with and without ␣-sy- tients with dementia with Lewy bodies, 5 patients with nuclein pathology. However, there are significantly higher Parkinson disease, and 8 control subjects. Protein ex- levels of the respiratory chain subunits in neurons con- pression was determined using immunocytochemistry fol- taining ␣-synuclein pathology. lowed by densometric analysis. Conclusions: The finding of increased levels of respi- Patients: We examined single substantia nigra neu- ratory chain complex subunits within neurons contain- rons from 5 patients with idiopathic Parkinson disease ing ␣-synuclein does not support a direct association be- (mean age, 81.2 years), 8 patients with dementia with tween mitochondrial respiratory chain dysfunction and Lewy bodies (mean age, 75 years), and 8 neurologically the formation of ␣-synuclein pathology. and pathologically normal control subjects (mean age, 74.5 years). The control cases showed minimal Lewy body Arch Neurol.
    [Show full text]
  • Neuromelanin, Neurotransmitter Status and Brainstem Location Determine the Differential Vulnerability of Catecholaminergic Neurons to Mitochondrial DNA Deletions
    UC San Diego UC San Diego Previously Published Works Title Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions Permalink https://escholarship.org/uc/item/8jz0f449 Journal Molecular Brain, 4(1) ISSN 1756-6606 Authors Elstner, Matthias Müller, Sarina K Leidolt, Lars et al. Publication Date 2011-12-21 DOI http://dx.doi.org/10.1186/1756-6606-4-43 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Elstner et al. Molecular Brain 2011, 4:43 http://www.molecularbrain.com/content/4/1/43 SHORTREPORT Open Access Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions Matthias Elstner1,2, Sarina K Müller1, Lars Leidolt1, Christoph Laub1,2, Lena Krieg1, Falk Schlaudraff3, Birgit Liss3, Chris Morris4,5, Douglass M Turnbull4,6, Eliezer Masliah7, Holger Prokisch8,9, Thomas Klopstock1,2† and Andreas Bender1,10*† Abstract Background: Deletions of the mitochondrial DNA (mtDNA) accumulate to high levels in dopaminergic neurons of the substantia nigra pars compacta (SNc) in normal aging and in patients with Parkinson’s disease (PD). Human nigral neurons characteristically contain the pigment neuromelanin (NM), which is believed to alter the cellular redox-status. The impact of neuronal pigmentation, neurotransmitter status and brainstem location on the susceptibility to mtDNA damage remains unclear. We quantified mtDNA deletions (ΔmtDNA) in single pigmented and non-pigmented catecholaminergic, as well as non-catecholaminergic neurons of the human SNc, the ventral tegmental area (VTA) and the locus coeruleus (LC), using laser capture microdissection and single-cell real-time PCR.
    [Show full text]